Annual biosimilar rituximab in seropositive RA: a four-year real-world study
Published in Clinical Rheumatology — what four years of annual biosimilar rituximab retreatment showed for disease control and safety in seropositive rheumatoid arthritis, and why real-world evidence still matters beside the trial literature.